Evidence map›Paper›PMID 21545576›Full record

ReviewBritish journal of pharmacology2012

Resistin: functional roles and therapeutic considerations for cardiovascular disease.

Md S Jamaluddin, Sarah M Weakley, Qizhi Yao, Changyi Chen

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in British journal of pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 228 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
228citing papers in PubMed, 6 pooled it
11.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

228 citing papers in PubMed, 6 syntheses or guidelines pooled it, 508 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Comparative Effects ofNutrients · 2024
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Beneficial Effects of n-3 Fatty Acids on Cardiometabolic and Inflammatory Markers in Type 2 Diabetes Mellitus: A Clinical Trial.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2017
    Trial
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Biomarkers of Cardiovascular Stress: A Historical Review.Journal of cardiovascular development and disease · 2026
    Review
  19. Review
  20. Article

168 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Md S JamaluddinMolecular Surgeon Research Center, Division of Vascular Surgery and Endovascular Therapy, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA.
Sarah M Weakley
Qizhi Yao
Changyi Chen
Baylor College of Medicine · US

Funding

Effects of HAART drugs on endothelial dysfunction of pu*R01HL083471 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI CHEN, CHANGYI · 2005 to 2009
$1.8M
Molecular Surgeon Research Training on Vascular DiseaseT32HL083774 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI CHEN, CHANGYI · 2008 to 2012
$970k
NHLBI NIH HHS R01 HL083471NHLBI NIH HHS R01HL083471NHLBI NIH HHS T32 HL083774NHLBI NIH HHS T32HL083774
6 · The paper itself

Abstract

unlabelledResistin, originally described as an adipocyte-specific hormone, has been suggested to be an important link between obesity, insulin resistance and diabetes. Although its expression was initially defined in adipocytes, significant levels of resistin expression in humans are mainly found in mononuclear leukocytes, macrophages, spleen and bone marrow cells. Increasing evidence indicates that resistin plays important regulatory roles apart from its role in insulin resistance and diabetes in a variety of biological processes: atherosclerosis and cardiovascular disease (CVD), non-alcoholic fatty liver disease, autoimmune disease, malignancy, asthma, inflammatory bowel disease and chronic kidney disease. As CVD accounts for a significant amount of morbidity and mortality in patients with diabetes and without diabetes, it is important to understand the role that adipokines such as resistin play in the cardiovascular system. Evidence suggests that resistin is involved in pathological processes leading to CVD including inflammation, endothelial dysfunction, thrombosis, angiogenesis and smooth muscle cell dysfunction. The modes of action and signalling pathways whereby resistin interacts with its target cells are beginning to be understood. In this review, the current knowledge about the functions and pathophysiological implications of resistin in CVD development is summarized; clinical translations, therapeutic considerations and future directions in the field of resistin research are discussed. LINKED ARTICLES: This article is part of a themed section on Fat and Vascular Responsiveness. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.165.issue-3.

Indexed as

AnimalsCardiovascular DiseasesCytokinesEndothelial CellsHumansMacrophagesMuscle, Smooth, VascularMyocytes, Smooth MuscleNeovascularization, PhysiologicResistinCytokinesResistin

Identifiers

PMID21545576
PMCPMC3315035
OpenAlexW1944309693

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.